News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Basilea Pharmaceutica Release: FDA Accepts for Review the Complete Response to Ceftobiprole NDA Approvable Letter
September 15, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BASEL, SWITZERLAND--(Marketwire - September 15, 2008) - Basilea Pharmaceutica Ltd. announces that the Food and Drug Administration (FDA) has accepted for review the Complete Response to the ceftobiprole New Drug Application (NDA) Approvable Letter.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Government
Chaos at CDC Continues as Hundreds Fired, Rehired
October 13, 2025
·
2 min read
·
Tristan Manalac
FDA
Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off
October 13, 2025
·
4 min read
·
Heather McKenzie
Rare Diseases
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
October 13, 2025
·
7 min read
·
Tristan Manalac
BIOSECURE Act
The BIOSECURE Act Is Back, as Congress Tacks New Version On to Broader Defense Bill
October 10, 2025
·
1 min read
·
Annalee Armstrong